|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
|
SE8804164A0
(sv)
|
1988-11-17 |
1990-05-18 |
Per Prisell |
Farmaceutisk beredning
|
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
|
US5177197A
(en)
|
1990-02-27 |
1993-01-05 |
Ludwig Institute For Cancer Research |
Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
|
|
US5229495A
(en)
|
1991-06-18 |
1993-07-20 |
Ludwig Institute For Cancer Research |
Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
|
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
DK0662146T3
(da)
|
1992-09-03 |
2000-11-13 |
Univ California |
Dorsalvævpåvirkende faktor og præparat
|
|
US5453492A
(en)
|
1993-07-28 |
1995-09-26 |
La Jolla Cancer Research Foundation |
60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
|
|
DE69523750T2
(de)
|
1994-05-04 |
2002-08-01 |
Mount Sinai Hospital Corp., Toronto |
Modulatoren der cytokine der tgf-beta überfamilie und verfahren zu ihrer bestimmung
|
|
US5616561A
(en)
|
1995-03-31 |
1997-04-01 |
Regents Of The University Of California |
TGF-β antagonists as mitigators of radiation-induced tissue damage
|
|
NZ500577A
(en)
|
1997-04-29 |
2001-02-23 |
Regeneron Pharma |
Human cerberus protein that regulates cell function, induce neural development or antagonise bone morphogenic proteins
|
|
EP0991759A1
(en)
|
1997-06-06 |
2000-04-12 |
Regeneron Pharmaceuticals, Inc. |
Ntn-2 member of tnf ligand family
|
|
US5935852A
(en)
|
1997-07-03 |
1999-08-10 |
Genetics Institute, Inc. |
DNA molecules encoding mammalian cerberus-like proteins
|
|
WO1999061044A1
(en)
|
1998-05-28 |
1999-12-02 |
The Board Of Trustees Of The University Of Arkansas |
Noggin and antagonists of bone morphogenetic proteins to suppress pathologic bone resorption
|
|
WO2000022909A2
(en)
|
1998-10-19 |
2000-04-27 |
Biotech Australia Pty. Limited |
Systems for oral delivery
|
|
ES2639020T3
(es)
|
1998-11-27 |
2017-10-25 |
Ucb Pharma S.A. |
Composiciones y métodos para incrementar la mineralización de la substancia ósea
|
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
|
AU3511100A
(en)
|
1999-03-12 |
2000-10-04 |
Regeneron Pharmaceuticals, Inc. |
Novel nucleic acids and polypeptides
|
|
US7358056B1
(en)
|
1999-08-30 |
2008-04-15 |
Signal Pharmaceuticals |
Methods for modulating signal transduction mediated by TGF-β and related proteins
|
|
WO2001047944A2
(en)
|
1999-12-28 |
2001-07-05 |
Curagen Corporation |
Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
|
|
US20020168638A1
(en)
|
2000-01-24 |
2002-11-14 |
Robert Schlegel |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
|
|
WO2001055388A1
(en)
|
2000-01-31 |
2001-08-02 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
|
EP1290217A2
(en)
|
2000-02-04 |
2003-03-12 |
Aeomica, Inc. |
Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
|
|
IL152785A0
(en)
|
2000-05-12 |
2003-06-24 |
Univ Utah Res Found |
Compositions and methods for cell dedifferentiation and tissue regeneration
|
|
US20040087016A1
(en)
|
2000-05-12 |
2004-05-06 |
University Of Utah Research Foundation |
Compositions and methods for cell dedifferentiation and tissue regeneration
|
|
EP1290169A2
(en)
|
2000-06-01 |
2003-03-12 |
Amgen, Inc. |
Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
|
|
JP2004520005A
(ja)
|
2000-06-19 |
2004-07-08 |
エフ．ホフマン−ラ ロシュ アーゲー |
オステオレビン遺伝子多型性
|
|
EP1370287A2
(en)
|
2000-12-01 |
2003-12-17 |
Wyeth |
Method and composition for modulating bone growth
|
|
EP1357828A2
(en)
|
2001-01-12 |
2003-11-05 |
University of Medicine and Dentistry of New Jersey |
Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
|
|
CA2465499A1
(en)
|
2001-11-08 |
2003-05-15 |
Merck & Co., Inc. |
Compositions and methods for treating osteoporosis
|
|
WO2003054152A2
(en)
|
2001-12-10 |
2003-07-03 |
Nuvelo, Inc. |
Novel nucleic acids and polypeptides
|
|
GB0130738D0
(en)
|
2001-12-21 |
2002-02-06 |
Serono Internat S A |
Protein
|
|
GB2385052A
(en)
|
2002-02-05 |
2003-08-13 |
Leuven K U Res & Dev |
Treatment of spondyloarthropathies
|
|
US20030186915A1
(en)
|
2002-02-11 |
2003-10-02 |
Yang Pan |
Regulatory polynucleotides and uses thereof
|
|
JP2005253301A
(ja)
|
2002-02-20 |
2005-09-22 |
Taisho Pharmaceut Co Ltd |
骨形成蛋白結合領域を有する蛋白質及びそれをコードする遺伝子
|
|
WO2003073991A2
(en)
|
2002-03-01 |
2003-09-12 |
Celltech R & D, Inc. |
Methods to increase or decrease bone density
|
|
WO2003087763A2
(en)
|
2002-04-03 |
2003-10-23 |
Celltech R & D, Inc. |
Association of polymorphisms in the sost gene region with bone mineral density
|
|
WO2003099992A2
(en)
|
2002-05-17 |
2003-12-04 |
Wyeth |
Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
|
|
US20040023356A1
(en)
|
2002-06-14 |
2004-02-05 |
Robb Krumlauf |
Wise/Sost nucleic acid sequences and amino acid sequences
|
|
WO2004041277A1
(en)
|
2002-11-01 |
2004-05-21 |
Merck & Co., Inc. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
|
US20060276385A1
(en)
|
2003-01-13 |
2006-12-07 |
Hanjoong Jo |
Anti-inflammatory agents and methods of their use
|
|
EP1608399B1
(en)
|
2003-03-14 |
2012-01-11 |
Ucb Manufacturing, Inc. |
Complex of sclerostin and noggin or chordin, and agents that modulate the formation of said complex
|
|
EP1622567B1
(en)
|
2003-05-07 |
2013-07-24 |
Merck Sharp & Dohme Corp. |
Androgen receptor modulators and methods of use thereof
|
|
CN1835974A
(zh)
|
2003-06-16 |
2006-09-20 |
细胞技术研究与发展公司 |
对硬化素特异的抗体和用于增加骨矿化的方法
|
|
WO2005023311A2
(en)
|
2003-09-11 |
2005-03-17 |
Association Francaise Retinitis Pigmentosa (Afrp) |
Novel targets for the treatment of retina diseases
|
|
US8461155B2
(en)
|
2003-09-22 |
2013-06-11 |
University Of Connecticut |
Sclerostin and the inhibition of WNT signaling and bone formation
|
|
WO2005041857A2
(en)
|
2003-10-07 |
2005-05-12 |
Quark Biotech, Inc. |
Bone morphogenetic protein (bmp) 2a and uses thereof
|
|
CA2566746A1
(en)
|
2004-05-14 |
2005-12-01 |
Baylor College Of Medicine |
Beta adrenergic drug conjugated to bone targeting moiety for modulating bone mass
|
|
CA2567805A1
(en)
|
2004-05-27 |
2005-12-15 |
Acceleron Pharma Inc. |
Tgf derepressors and uses related thereto
|
|
AU2006223579A1
(en)
|
2005-03-11 |
2006-09-21 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
|
US7592429B2
(en)
*
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
|
US20060293667A1
(en)
|
2005-05-19 |
2006-12-28 |
Agnes Vignery |
Bone implant device and methods of using same
|
|
WO2006135734A2
(en)
|
2005-06-10 |
2006-12-21 |
The Regents Of The University Of California |
Compositions and methods for altering bone density and bone patterning
|
|
EP1981910B1
(en)
|
2006-01-13 |
2013-06-26 |
A Chan Holding B.V. |
Method for identifying inhibitor of the glypican-sclerostin interaction
|
|
US20100036091A1
(en)
|
2006-11-10 |
2010-02-11 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
|
WO2008133722A2
(en)
|
2006-11-10 |
2008-11-06 |
Ucb Pharma S.A. |
Anti human sclerostin antibodies
|
|
SI3345607T1
(sl)
|
2006-12-29 |
2023-03-31 |
Ossifi-Mab Llc |
Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
|
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
|
AU2008338464A1
(en)
|
2007-12-14 |
2009-06-25 |
Amgen Inc. |
Method for treating bone fracture with anti-sclerostin antibodies
|
|
WO2010100200A2
(en)
*
|
2009-03-05 |
2010-09-10 |
Novartis Ag |
Lyophilised antibody formulation
|
|
WO2010115932A1
(en)
|
2009-04-08 |
2010-10-14 |
Novartis Ag |
Combination for the treatment of bone loss
|
|
SMT202000095T1
(it)
|
2010-05-14 |
2020-03-13 |
Amgen Inc |
Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
|
|
US9617323B2
(en)
|
2010-06-07 |
2017-04-11 |
Joshua Rabbani |
Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
|
|
EP3838922A1
(en)
|
2010-10-27 |
2021-06-23 |
Amgen Inc. |
Dkk1 antibodies and methods of use
|
|
JP2014509588A
(ja)
|
2011-03-01 |
2014-04-21 |
アムジエン・インコーポレーテツド |
二特異性結合剤
|
|
US9145457B2
(en)
|
2011-03-25 |
2015-09-29 |
Amgen Inc. |
Sclerostin antibody crystals and formulations thereof
|
|
ES2823240T3
(es)
|
2011-04-19 |
2021-05-06 |
Amgen Inc |
Método para el tratamiento de la osteoporosis
|
|
ES2667554T3
(es)
|
2011-08-04 |
2018-05-11 |
Amgen Inc. |
Método para el tratamiento de los defectos de espacio óseo
|
|
KR20190120401A
(ko)
|
2011-12-28 |
2019-10-23 |
암젠 인크 |
항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
|
|
JP6770312B2
(ja)
|
2012-07-05 |
2020-10-14 |
ユセベ ファルマ ソシエテ アノニム |
骨疾患の治療
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
|
ES2964640T3
(es)
|
2015-08-13 |
2024-04-08 |
Amgen Inc |
Filtración en profundidad cargada de proteínas de unión al antígeno
|
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
|
MA45921A
(fr)
|
2016-08-08 |
2019-06-19 |
Amgen Inc |
Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine.
|
|
AU2017381433B2
(en)
|
2016-12-21 |
2024-11-14 |
Mereo Biopharma 3 Limited |
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
|
|
US10961305B2
(en)
*
|
2016-12-21 |
2021-03-30 |
Mereo Biopharma 3 Limited |
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
|
|
AU2018235928B2
(en)
|
2017-03-14 |
2023-09-21 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
KR20200034748A
(ko)
|
2017-07-27 |
2020-03-31 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
Sost 항체 약학적 조성물 및 그의 용도
|
|
US12325737B2
(en)
|
2018-03-26 |
2025-06-10 |
Amgen Inc. |
Total afucosylated glycoforms of antibodies produced in cell culture
|
|
EP3774879B1
(en)
|
2018-03-30 |
2026-01-28 |
Amgen Inc. |
C-terminal antibody variants
|
|
CA3108693A1
(en)
|
2018-08-10 |
2020-02-13 |
Ashutosh Sharma |
Method of preparing an antibody pharmaceutical formulation
|